Literature DB >> 26124326

SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.

Danyelle Winchester1, Luisel Ricks-Santi2, Tshela Mason3, Muneer Abbas4, Robert L Copeland5, Desta Beyene6, Emmanuel Y Jingwi6, Georgia M Dunston7, Yasmine M Kanaan8.   

Abstract

BACKGROUND/AIM: Several studies reported that patients with benign prostatic hyperplasia (BPH) experienced a 10% increased incidence of prostate cancer (PCa) after the first 5 years of diagnosis. We investigated the association between single nucleotide polymorphisms (SNPs) in the promoter of Serine Protease Inhibitor Kazal Type 1 (SPINK1) and the increased risk of BPH and PCa.
MATERIALS AND METHODS: We genotyped three SNPs in a cases-control study, including BPH and PCa cases. Multiple logistic regression models were applied to analyze clinical and genotypic data.
RESULTS: We found an inverse association between SNP rs10035432 and BPH under the log-additive (p=0.007) model. No association was found between these SNPs and PCa risk. However, we observed a possible association between rs1432982 and lower-grade PCa (p=0.05) under the recessive model.
CONCLUSION: SPINK1 promoter variants are likely to be associated with the risk of BPH. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  African American; BPH; Gleason; SNPs; SPINK1; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26124326      PMCID: PMC4545211     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  44 in total

1.  SNPStats: a web tool for the analysis of association studies.

Authors:  Xavier Solé; Elisabet Guinó; Joan Valls; Raquel Iniesta; Víctor Moreno
Journal:  Bioinformatics       Date:  2006-05-23       Impact factor: 6.937

2.  Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men.

Authors:  Asmahan Ali El Ezzi; Wissam Rateeb Zaidan; Mohammed Ahmed El-Saidi; Nabil Al-Ahmadieh; Jeffrey Benjamin Mortenson; Ruhul Haque Kuddus
Journal:  Asian Pac J Cancer Prev       Date:  2014

3.  Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.

Authors:  Gai-Ping Wang; Cun-Shuan Xu
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 4.  Pharmacogenetics of human androgens and prostatic diseases.

Authors:  G Novelli; K Margiotti; F Sangiuolo; J K Reichardt
Journal:  Pharmacogenomics       Date:  2001-02       Impact factor: 2.533

5.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.

Authors:  Annukka Paju; Kristina Hotakainen; Yue Cao; Timo Laurila; Virgil Gadaleanu; Akseli Hemminki; Ulf-Håkan Stenman; Anders Bjartell
Journal:  Eur Urol       Date:  2007-02-05       Impact factor: 20.096

6.  Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Leni Kauko; Pauliina Helo; Henna Kekki; Angel M Cronin; Andrew J Vickers; Martti Nurmi; Kalle Alanen; Anders Bjartell; Kim Pettersson
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

Review 7.  Tumor-associated trypsin inhibitor.

Authors:  Ulf-Håkan Stenman
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

8.  Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls.

Authors:  Manzoor Ahmad; Nida Suhail; Tariq Mansoor; Naheed Banu; Shamshad Ahmad
Journal:  Indian J Clin Biochem       Date:  2012-06-12

9.  Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.

Authors:  Wendy Weijia Soon; Lance David Miller; Michael A Black; Cyril Dalmasso; Xiu Bin Chan; Brendan Pang; Chee Wee Ong; Manuel Salto-Tellez; Kartiki V Desai; Edison T Liu
Journal:  EMBO Mol Med       Date:  2011-06-08       Impact factor: 12.137

10.  Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population.

Authors:  Hosik Seok; Koo Han Yoo; Young Ock Kim; Joo-Ho Chung
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

View more
  2 in total

1.  Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.

Authors:  Jacklyn N Hellwege; Sarah Stallings; Eric S Torstenson; Robert Carroll; Kenneth M Borthwick; Murray H Brilliant; David Crosslin; Adam Gordon; George Hripcsak; Gail P Jarvik; James G Linneman; Parimala Devi; Peggy L Peissig; Patrick A M Sleiman; Hakon Hakonarson; Marylyn D Ritchie; Shefali Setia Verma; Ning Shang; Josh C Denny; Dan M Roden; Digna R Velez Edwards; Todd L Edwards
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

2.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Authors:  Deli Liu; Jonathan E Shoag; Daniel Poliak; Ramy S Goueli; Vaishali Ravikumar; David Redmond; Aram Vosoughi; Jacqueline Fontugne; Heng Pan; Daniel Lee; Domonique Thomas; Keyan Salari; Zongwei Wang; Alessandro Romanel; Alexis Te; Richard Lee; Bilal Chughtai; Aria F Olumi; Juan Miguel Mosquera; Francesca Demichelis; Olivier Elemento; Mark A Rubin; Andrea Sboner; Christopher E Barbieri
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.